Keyphrases
Type I Diabetes
100%
Type 1 Diabetes Mellitus (T1DM)
100%
Metabolic Indices
100%
Preventive Treatment
100%
Treatment Effect
100%
Tezepelumab
100%
High-risk Individuals
100%
C-peptide
66%
Diabetes
50%
Prevention Trials
50%
Metabolic Endpoints
50%
TrialNet
16%
Placebo
16%
Multicenter Clinical Trial
16%
Disease-modifying Therapy
16%
Natural History Study
16%
Prevention Studies
16%
Response to Immunotherapy
16%
Proportional Hazards Model
16%
T-test
16%
Inclusion Criteria
16%
Chi-square Statistic
16%
Combined Measures
16%
Type 1 Diabetes Management
16%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
100%
Prophylaxis
100%
Treatment Effect
100%
Teplizumab
85%
C-Peptide
57%
Diabetes
42%
Clinical Trial
14%
Arm
14%
Diabetes Prevention
14%
Infusion
14%
Proportional Hazards Model
14%
Student T Test
14%
Disease Modifying Therapy
14%
Placebo
14%
Immunotherapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Insulin Dependent Diabetes Mellitus
100%
Teplizumab
85%
C Peptide
57%
Clinical Trial
14%
Placebo
14%
Disease
14%
Immunotherapy
14%
Neuroscience
Teplizumab
100%
C Peptide
66%
Immunotherapy
16%
Placebo
16%
Biochemistry, Genetics and Molecular Biology
Teplizumab
100%
C-Peptide
66%
Clinical Trial
16%